Merck Walks Away From Revolution Medicines Talks, Triggering Biotech Deal-Premium Reset

Merck $MRK is no longer in talks to buy Revolution Medicines $RVMD, according to a Wall Street Journal report. The talks reportedly cooled over price, and notes say talks could restart or another bidder could show up.

Why this matters to markets

This is a classic M and A premium unwind. When a rumored buyout fades, the target often drops as the takeover premium comes out. For Merck, walking away can be read as valuation discipline, but it also keeps the pressure on to build the post-Keytruda growth pipeline through other deals or internal R and D wins.

Winners

Valuation discipline, capital allocation focus

If Merck avoids overpaying, investors can reward financial discipline. Other large pharma that stay ...